ArticleFrontiers in oncology2026
Hybrid handcrafted and deep feature fusion for automated acute myeloid leukemia classification using TCMA-Net on a class-balanced dataset.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a life-threatening hematological malignancy that requires accurate and timely diagnosis for effective clinical management. However, conventional cytomorphological analysis is time-consuming, subjective, and highly dependent on expert interpretation. Existing artificial intelligence-based approaches are often limited by severe class imbalance and inadequate feature representation, which restrict their generalization capability. To address these challenges, this study proposes a robust and high-performance AML classification framework based on hybrid feature fusion and deep learning. The proposed approach integrates handcrafted features with deep representations extracted from DenseNet201 and MobileNetV2 to form the Hybrid AML Descriptor Network (HADNet), which is further combined with the Transformer-based Tri block Convolutional Multi head Attention Network (TCMA-Net) classifier to capture both local and global contextual information. In addition, a Synthetic Acquisition Artifact Augmentation (S3A) strategy is introduced to mitigate class imbalance by generating realistic variations in illumination and noise. Extensive experiments were conducted on the AML cytomorphology Ludwig Maximilian University (LMU) dataset, where the proposed framework achieved a testing accuracy of 99.20%, outperforming traditional machine learning models and deep learning baselines. The effectiveness of the approach is further validated through ablation studies and external evaluation on the acute lymphoblastic leukemia (ALL) dataset, demonstrating strong robustness and generalization across different data distributions. Overall, the results indicate that the integration of handcrafted and deep features significantly enhances classification performance, stability, and reliability. The proposed framework provides a promising solution for automated AML diagnosis and has the potential to support clinical decision-making systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.